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Abstract The eye, like the brain and reproductive organs,
possesses inherent immune privilege, and inflammation is
self-regulated so as to preserve the organ functions. Studies
over the past 30 years have provided insights of the
multiple mechanisms of immune privilege. At present,
three major lines of thought prevail regarding the molecular
mechanisms of immune privilege in the eye: there are (1)
anatomical, cellular, and molecular barriers in the eye; (2)
eye-derived immunological tolerance, the so-called anterior
chamber-associated immune deviation; and (3) immune
suppressive intraocular microenvironment. In this review,
the mechanisms of immune privilege that have been learned
from ocular inflammation animal models, especially corne-
al transplantation, are described. Roles of new B7 family
molecules on local immune regulation within the cornea are
also introduced.
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The eye is constructed from tissue with little or no capacity
for regeneration, specifically, corneal endothelial cells and
retinal cells cannot proliferate in vivo. For that reason,
ocular tissue damage due to excessive inflammation can
lead to loss of sight. Accordingly, the eye, like the brain and
reproductive organs, is endowed with immune privilege [1,
2], and inflammation is self-regulated so as to preserve the
organ functions. Animal studies have shown that when eyes
are deprived of immune privilege, autoimmune intraocular
inflammation readily occurs, and that condition is severe
and intractable [1, 2]. In addition, corneal transplants are
the least-rejected among all organ transplants, and that
characteristic is also attributable to immune privilege [1, 2].
When corneal transplantation is performed on eyes that
have been deprived of immune privilege, the rejection rate
b e c o m e sa sh i g ha si nt h ec a s e so fh e a r ta n ds k i n
transplantation [1–3].
The concept of immune privilege was first proposed in
the 1940s by the Nobel laureate, P.B. Medawar, and
colleagues [4]. They recognized the extended survival of
foreign tissue grafts placed in the anterior chamber of the
eye or in the brain. At that time, it was thought that the eyes
and brain had an anatomical barrier and that the lesser
rejection of transplants was due to immunological igno-
rance [4]. However, more recently, it has been elucidated by
Streilein and colleagues, that it is not just due to
immunological ignorance, but also an active immune
suppression mechanism [1, 2]. Progress has been made in
analyzing the regulatory mechanisms in ocular inflamma-
tion by using animal models of corneal transplantation and
autoimmune uveitis. At present, three major lines of
thought prevail regarding the molecular mechanisms of
immune privilege in the eye: (1) there are anatomical,
cellular, and molecular barriers in the eye; (2) eye-derived
immunological tolerance, the so-called anterior chamber-
associated immune deviation (ACAID); and (3) immune
suppressive microenvironment in the eye. Here, I review
the mechanisms of immune privilege in the eye by using a
corneal transplantation model and also describe role of new
B7 family molecules on local immune regulation in the
anterior segment.
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The cornea contains no blood or lymph vessels; therefore,
considerable time passes after corneal transplantation
before antigen recognition occurs in the regional lymph
nodes and effector cells reach the graft. In addition, the
corneal epithelial cells, keratocytes, and endothelial cells,
do not express MHC class II molecules and also express
only low levels of MHC class I molecules [5, 6]. This
means that the main targets of a rejection reaction are not
MHC antigens, but the minor H antigens in the corneal
allografts [7]. When corneal endothelial cells were simul-
taneously exposed to interferon (IFN)-γ and tumor necrosis
factor (TNF)-α, they expressed MHC class II molecules but
not the class II transactivator gene or invariant chain [8]. In
addition, MHC class II-positive dendritic cells and macro-
phages are absent in normal cornea, except in the peripheral
region of the cornea [5]. There are small numbers of bone
marrow-derived cells that still do not express MHC class II
antigens in normal cornea, but controversy remains over
whether they play the role of mature antigen-presenting
cells (APCs), and it is thought that there are no donor-
derived mature APCs in the donor cornea [9]. Therefore,
the role of antigen presentation in the regional lymph nodes
after corneal transplantation is carried out mainly by host-
derived APCs rather than donor-derived APCs, and it is
thought that recognition of donor antigens occurs in indirect
fashion, by host CD4
+ T cells via donor antigen-bearing host
MHC class II molecules on host APCs [7, 10]. The main
effector mechanism of rejection reactions in corneal trans-
plantation is thought to be delayed-type hypersensitivity
(DTH), rather than cytotoxic T cells (CTL), with the reaction
targeting the donor minor H antigens rather than the donor
MHC molecules [7, 10]. Thus, it can be surmised that the
post-transplantationimmuneresponseisweakerinthecaseof
corneal transplants compared with other organ grafts because
of not only the anatomicalcharacteristics of thecornealtissue
but also its low antigenicity and the above-described
mechanisms of antigen presentation and recognition.
Anterior chamber-associated immune deviation
Anterior chamber-associated immune deviation refers to a
phenomenon in which antigen-specific systemic immuno-
logical tolerance is induced to an antigen that has been
introduced to the anterior chamber in rodent eyes [1, 2].
ACAID is a phenomenon in which antibody responses are
preserved while cellular responses such as DTH and CTL
are suppressed. It is known that similar phenomenon occurs
even in relation to an antigen that has been introduced the
vitreous cavity or the subretinal space of the eye [1].
ACAID is induced in relation to various kinds of antigens,
including allo-transplantation antigens, soluble protein
antigens, viral antigens, and tumor antigens, and it has
been demonstrated to be involved in various events such as
acceptance of corneal transplants, autoimmune uveitis,
acute retinal necrosis (ARN) in a fellow eye that experi-
enced herpes virus infection in the anterior segment, or
progression of intraocular malignant melanoma, in mouse
models [1]. Induction of ACAID to autoantigens is
reportedly induced by inoculating the anterior chamber
with retinal autoantigens followed by a demonstration that
such mice are subsequently resistant to the induction of
experimental autoimmune uveitis by immunization with the
same autoantigen [11]. In several areas, the findings from
studies in the mouse model can be extrapolated to
understanding the pathogenesis in human patients. For
example, patients with ARN develop an ACAID-like
response to viral antigens in the intraocular compartment
that disappears as the disease resolves [12–14].
The eye and the spleen are involved in the induction of
ACAID (Fig. 1). Transforming growth factor (TGF)-β2 and
thrombospondin (TSP)-1 in the anterior chamber are
involved in the induction of APC mediators of ACAID,
and eye-derived APCs such as macrophages that express
F4/80 molecule pass across the trabecular meshwork, enter
the bloodstream, and reach the spleen [15–18]. The eye-
derived APCs that reach the marginal zone in the spleen
produce TGF-β, macrophage inflammatory protein 2, and
CXC-chemokine ligand 2 and attract natural killer T (NKT)
cells [19]. Then CD1d molecules that are expressed on the
surface of the APCs bind with receptors that are expressed
on the surface of the NKT cells, thereby presenting the
antigens [20]. NKT cells produce TGF-β, IL-10, RANTES,
CC-chemokine ligand 5, and TSP-1 [21, 22]. When
marginal zone B cells are also present in this environment
rich in immunomodulatory factors, clusters comprised of
these three cell types form [23, 24]. When CD4+ and/or
CD8+ T cells that are attracted to those clusters recognize
the antigens being presented by the eye-derived APCs and
the marginal zone B cells, they differentiate into ACAID-
inducing regulatory T cells (ACAID-Treg). At that time,
Qa-1 molecule on the surface of the marginal zone B cells
function as antigen-presenting molecule. CD4+ ACAID-
Treg inhibit the differentiation for Th1 cells in secondary
lymph tissues such as lymph nodes, while CD8+ ACAID-
Treg inhibit the function of effector T cells (Th1 and Th2)
in the local site [25, 26]. It was recently reported that thymo-
cytes and splenic γδ T cells are also necessary for induction
of ACAID, and it can be understood that immune privilege
in the eye is sustained through the cooperation of various
cells from organs other than the eye itself (Fig. 1)[ 1, 2, 27].
Following corneal transplantation, ACAID is induced by
the mechanism described above after the transplantation
antigens on the endothelial surface of the cornea are taken
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transported to the spleen [1, 2]. Induction of ACAID leads
to inhibition of the allo-antigen specific DTH and results in
long-term survival of the graft [10, 28, 29]. ACAID cannot
be induced in the case of infiltration of lymph vessels into
the cornea, suturing, inflammation, trauma, or neurotomy in
the cornea. In this situation, the eye is said to be at high risk
of rejection, and in animal models of corneal transplanta-
tion, the rejection rate within 3 weeks after transplantation
is 100% [3, 28]. Clinically, as well, rejection reactions
readily occur in patients presenting this condition.
Molecules maintaining an immune suppressive
intraocular microenvironment
As the anatomical and cellular barriers, or ACAID, are not
absolute, innate and adaptive immune cells and molecules
can still access the eye. In response to threats to vision, the
eye has soluble and cell surface immunomodulatory factors
that act within the oculi to suppress cells and molecules that
mediate innate and adaptive immune inflammation [1]. This
intraocular milieu is called the immune suppressive
microenvironment. The functions of the various cells and
factors that manage natural immunity and acquired immu-
nity are inhibited by the various factors that are expressed
in the anterior segment and are shown in Table 1 [1, 2, 15,
16, 30–39]. Among those factors, α-melanocyte-stimulating
hormone, vasoactive intestinal peptide, calcitonin gene-
related peptide, TGF-β2, and TSP-1 regulate the functions
of macrophages and dendritic cells. TGF-β2 and TSP-1 are
essential factors for the induction of ACAID as described in
the previous section. As shown in Table 1, various
immunomodulatory factors are expressed in corneal endo-
thelial cells and iris–ciliary body. We recently elucidated
that the inhibitory costimulatory signaling molecules of the
B7 family are involved in immune suppression in the
cornea. Those molecules are introduced below.
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Regional Lymph Nodes
Th 0
Th 1
TGF-β2, TSP-1
+
Eye-derived APCs
Entering the bloodstream via the trabecular meshwork
Eye-derived APCs
Marginal Zone B cells
TGF-b, MIP-2, CXCL2,
IL-10, CCL-5, TSP-1 CD-1d
CD8+ Treg suppress 
effector T in the eye 
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Anterior Chamber
Infiltration of Th1 effector T cells 
in the eye
Fig. 1 Induction of ACAID. In the anterior chamber, which contains
transforming growth factor (TGF)-β2 and thrombospondin (TSP)-1,
the eye-derived antigen-presenting cells have captured antigens. The
eye-derived APCs enter the bloodstream, reach the marginal zone of
spleen, and produce TGF-β, macrophage inflammatory protein 2
(MIP-2), and CXC-chemokine ligand 2 (CXCL2). These cells attract
and bind, via CD1d molecules, to NKT cells. The NKT cells produce
TGF-β, IL-10, CC-chemokine ligand 5 (CCL5) and TSP-1; attract
marginal zone B cells; and then form clusters comprised of these three
cell types. T cells, which have presented the antigens in clusters, then
differentiate into ACAID-inducing regulatory T cells (ACAID-Treg).
CD4+ ACAID-Treg inhibit the differentiation of Th1 cells in the
lymph nodes, while CD8+ ACAID-Treg inhibit the function of
effector Th1 and Th2 cells in the local site
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B7-H1 (PD-L1) was identified as a new B7 family
molecule that binds to programmed death (PD)-1 on the
surface of activated T cells and sends inhibitory signals to
the T cells [40]. On the basis of the results generated in
various animal models of autoimmune diseases, it has been
reported that B7-H1 is involved in the induction of
peripheral immune tolerance [40, 41]. In ocular tissues,
B7-H1 is constitutively expressed in endothelial cells of the
cornea, some stromal cells, iris–ciliary body, and the neural
retina. The rejection reaction after corneal transplantation is
intensified by blockade of B7-H1 or PD-1 with antibodies
[39]. B7-H1 expressed in the cornea induces apoptosis of
PD-1-expressing T cells, and deletion of effector T cells in
the cornea results in inhibition in the effector phase of the
rejection reaction [39]. It is highly interesting that the T-cell
apoptosis mediated by B7-H1 has been only observed in
immune privileged tissues or sites such as tumors, liver, and
cornea so far [41, 42]. Corneal endothelial cells also
constitutively express Fas ligand, and apoptosis of effector
T cells is induced via Fas [35–37]. It is unclear whether, in
this state of the effector Tcells having been eliminated from
the eye, B7-H1 and Fas ligand interact on the surface of the
corneal endothelial cells (Fig. 2). On the other hand, the
previously described ACAID is induced even if the PD-1/
B7-H1 pathway is blocked. That is, the induction of
ACAID-Treg by the eye-derived APCs and spleen cells is
not dependent on the PD-1/B7-H1 pathway.
The culture system of corneal tissue and T cells in vitro
has been established and shown that B7-H1 expressed in
the cornea shows local immunosuppressive activity [39].
This system permits complete elimination of any involve-
ment of the secondary lymphatic organs and makes it
possible to isolate and analyze only the effector phase of
the rejection reaction when the corneal endothelial cells has
Corneal endothelium
T cells 
T cells
corneal 
corneal endothelial
cells
cells
corneal
stroma
B7-H1
PD-1
FasL
Fas
Apoptosis
Fig. 2 T-cell apoptosis medicat-
ed by B7-H1 expressed in
corneal endothelial cells.
B7-H1, which is constitutively
expressed in corneal endothelial
cells, induces apoptosis of
PD-1+T cells. Corneal endothe-
lial cells also constitutively
express Fas L, which is involved
in immune regulation in the
eye by inducing T-cell
apoptosis via Fas
Table 1 Immunomodulatory factors expressed in the anterior segment of the eye
Soluble factors in the anterior chamber (target cells/factors to suppress) Cell surface molecules of the cornea and iris–ciliary body
α-MSH (T cells, macrophages, neutrophils) B7-H1 (PD-L1) (T cells)
VIP (T cells) B7-H3 (?)
Somatostatin (T cells) B7-2 (via CTLA4) (T cells)
CGRP (macrophages) Fas L (CD95 L) (T cells, neutrophils)
TGF-β2 (T cells, macrophages, NK cells) MHC class Ib (T cells, NK cells)
TSP-1 (macrophages) CD46, CD55, CD59 (complement)
MIF (NK cells)
IL-1Ra (IL-1)
sFas L (T cells, neutrophils)
CD46, CD55, CD59, C3ib (complement)
α-MSH α-Melanocyte stimulating hormone, VIP vasoactive intestinal peptide, CGRP calcitonin gene-related peptide, TGF-β2 transforming
growth factor-β 2, TSP-1 thrombospondin, MIF macrophage migrating inhibitory factor, IL-1Ra interleukin 1 receptor antagonist, sFas L soluble
Fas ligand, CTLA4 cytotoxic T lymphocyte antigen 4
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B7-H1 expressed in the corneal cells not only inhibited
corneal endothelial damage by allo-reactive T cells but also
inhibited bystander damage caused by activated T cells that
are specific to third party antigen. In addition, PD-1 on the
surface of the T cells was up-regulated as a result of contact
with the corneal cells, thus accelerating apoptosis. More-
over, B7-H1 expression on epithelial cells was induced in
the presence of inflammatory cytokine such as IFN-γ, and
T-cell apoptosis mediated by B7-H1 and PD-1 was induced
in each of the epithelium, stroma, and endothelium of the
cornea. (Figure 3).
As described above, the PD-1/B7-H1 pathway is more
involved in interactions between the effector T cells and the
corneal cells within the eye than in the immune responses
in the secondary lymphatic organs [39]. Thus, these
molecules contribute to maintenance of the local immune
suppressive microenvironment in the eye.
ACAID induction mediated by B7-H3
B 7 - H 3w a sr e c e n t l yi d e n t i f i e da san e wB 7f a m i l y
molecule, but its receptor has not yet been identified [43].
There have been conflicting reports, based on different
experimental systems, as to whether B7-H3 is a costimu-
latory signal molecule that sends positive signals or
negative signals to T cells [43]. This is currently a source
of controversy. In the eye, B7-H3 is constitutively
expressed in corneal endothelial cells and the iris–ciliary
body, and that a rejection is induced after corneal
transplantation in experimental hosts to which anti-B7-H3
blocking antibody had been intraperitoneally administered
[44]. It is of interest that ACAID is not induced in such
animals administered with anti-B7-H3 antibody. That is,
B7-H3 is involved in induction of ACAID-Treg that are
dependent on the spleen and mediated by eye-derived
antigen-presenting cells, and it thus plays a different role
from that of B7-H1 [44]. Also, the possibility that B7-H3,
like the previously described B7-H1, plays a role in
eliminating or inhibiting effector immune cells within the
cornea remains to be established.
Conclusion
The eye, which is endowed with immune privilege, is a rare
organ that permits analysis of the self-regulatory mecha-
nisms for inflammation in organs. In particular, studies
using animal models of corneal transplantation have
revealed that a new molecule, B7-H1, induces apoptosis
of effector T cells via PD-1 and plays a role in immune
regulation in the cornea. In addition, we learned that
another new molecule, B7-H3, is also constitutively
expressed in the anterior segment of the eye and plays a
role in the induction of ACAID, which is an eye-derived
immunological tolerance. The normal eye possesses an
anatomical barrier mechanism, ACAID, and a molecular
mechanism of an immune suppressive intraocular microen-
vironment. It can be anticipated that understanding those
PD-1+ T cells
Corneal allografts
B7-H1+
deep stroma
& endothelium
epithelium
Induction of B7-H1expression 
on epithelium
B7-H1(-)
Up-regulation of
PD-1 expression on T cells
Induction of T cells-apoptosis
in all layers of the cornea
Fig. 3 Induction of B7-H1 expression in the corneal epithelium and
up-regulation of T-cell surface PD-1. B7-H1 is constitutively
expressed in the endothelial cells and stromal cells of the normal
cornea but not in the epithelial cells. PD-1 expression on the surface of
T cells is up-regulated by contact with corneal cells. In the presence of
IFN-γ, B7-H1 expression on epithelial cells is induced, and T-cell
apoptosis mediated by B7-H1 and PD-1 is induced in each of the
epithelium, stroma, and endothelium of the cornea
98 j ocul biol dis inform (2008) 1:94–100phenomena will contribute to the development of new
therapeutic approaches to tissue transplantation and auto-
immune disease of not only the eye but also of other organs.
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